Tbh, after reading the announcement again, it is very clear that RAP ought to consider strongly a clinical research PhD (ie a medical practitioner, preferably an experienced paediatrician or respiratory physician, with a clinical research PhD) with an appropriate skillset to lead their involvement in a second trial and do a dummy run perhaps, or more than one, to iron out potentially catastrophic variables.
Apologies if this was already done.
Tbh, after reading the announcement again, it is very clear that...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #